You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study

 

Online download statistics by month:

Online download statistics by month: June 2021 to January 2026

AbstractFullPdf
Jun 202134134581
Jul 202117017050
Aug 202111711620
Sep 2021898933
Oct 202116016033
Nov 2021909140
Dec 2021747618
Jan 2022627327
Feb 2022354018
Mar 2022576125
Apr 2022576329
May 2022545821
Jun 2022535422
Jul 2022444620
Aug 2022495019
Sep 2022494918
Oct 2022485017
Nov 2022303121
Dec 2022636327
Jan 2023464629
Feb 2023626215
Mar 2023283129
Apr 2023303019
May 2023424228
Jun 2023545528
Jul 2023414224
Aug 2023464620
Sep 2023434627
Oct 2023707019
Nov 202361619
Dec 2023474812
Jan 2024303115
Feb 2024434317
Mar 2024797960
Apr 2024535330
May 2024485019
Jun 2024646318
Jul 2024596023
Aug 2024434327
Sep 2024484827
Oct 2024494923
Nov 2024838425
Dec 2024626422
Jan 2025586236
Feb 202510510532
Mar 2025484828
Apr 202510310350
May 2025414220
Jun 2025444624
Jul 2025220
Sep 2025110
Jan 2026110
Total327633411294